US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutide

Makers of knockoff in-demand weight loss drugs are fast running out of options to manufacture them legitimately as a federal court this week dismissed an attempt by compounding pharmacies to continue to produce copycats of Novo Nordisk’s semaglutide while a lawsuit plays out.